menu search

Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
Company reports fourth quarter and full year 2022 XHANCE net revenue of $20.9 million and $76.3 million Company submitted sNDA for XHANCE label expansion in February 2023 Physicians diagnose chronic sinusitis 10 times more frequently than XHANCE’s current nasal polyps indication and there is no FDA-approved medication for these patients Conference call and webcast to […] The post Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights appeared first... Read More
Posted: Mar 7 2023, 12:00
Author Name: forextv
Views: 102634

Search within

Pages Search Results: